Modulation of Gut Microbiota by Rifaximin in PD Patients

Summary

The purposes of this clinical trial are to test 1. Whether 1-week rifaximin treatment is able to restore the gut microbiota in a long-term manner in people with Parkinson's disease? 2. Whether the restoration of gut microbiota in people with Parkinson's disease is associated with the reduction of systemic inflammation and circulating exosomal α-synuclein?

Timeline

Start

2019-05-13

Primary completion

2020-05-12

Completion

2020-12-01

Drugs

Indications